Skip to search formSkip to main contentSkip to account menu

Anti-sCLU Monoclonal Antibody AB-16B5

Known as: AB-16B5 
A humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies
Background. Secreted clusterin (sCLU) promotes survival and stimulates epithelial to mesenchymal transition (EMT) in cancer cells… 
2012
2012
Abstract LB-297: The EMT inhibitor AB-16B5 interacts with specific isoforms of secreted clusterin
2011
2011
Abstract LB-33: Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and…
Secreted clusterin (sCLU) exhibits elevated expression in several cancer indications. sCLU plays a pro-survival role in tumors… 
2010
2010
Detecting soluble clusterin in in-vitro and in-vivo models of prostate cancer.
PSA, the only relevant marker for prostate cancer, has a low predictive value; moreover its low threshold leads to unnecessary… 
2010
2010
Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition
Studies are increasingly implicating clusterin (CLU) as an important contributing factor in cancer promotion and invasion… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)